Subsequent events (Details) - Subsequent events. - USD ($) $ in Millions |
Feb. 07, 2020 |
Jan. 24, 2020 |
Jan. 13, 2020 |
|---|---|---|---|
| American Depository Shares (ADSs) | |||
| Net proceeds | $ 89.8 | ||
| American Depository Shares (ADSs) | Underwritten Public Offering | |||
| Issuance of common stock (in shares) | 21,000,000 | ||
| American Depository Shares (ADSs) | Over-Allotment Option | |||
| Issuance of common stock (in shares) | 3,150,000 | ||
| Astellas Pharma Inc. | |||
| Upfront payment received | $ 50.0 | ||
| Research funding | $ 7.5 |
| X | ||||||||||
- Definition Upfront payment received. No definition available.
|
| X | ||||||||||
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|